Oncology Infusion Centers
Outpatient infusion sites delivering chemotherapy and oncology biologic infusions.
Market snapshot
These figures describe Outpatient Infusion Centers (4.10.18), the segment that Oncology Infusion Centers sits within. They are not figures for Oncology Infusion Centers on its own.
- Market size
- ~$70B
- Growth
- ~5.4%CAGR (2017–22, nominal)
- Companies
- ~10,809 firms
Mapped to a broad 'all other outpatient care centers' code, so ~$70B / ~10,800 firms captures more than infusion alone. Still, the site-of-care shift out of the hospital and specialty/biologic drug growth make freestanding infusion the fast-growing core (~5.4%/yr), and it is an active consolidation theme (Option Care, PE-backed platforms).
NAICS 621498. U.S. Census Bureau, 2022 Statistics of U.S. Businesses; U.S. Census Bureau, 2022 Economic Census. A broad residual code that captures other outpatient care beyond infusion centers.
Business model & economics
Revenue model
Drug margin plus infusion-service reimbursement
Key economics
- Recurring revenue
- High
- EBITDA margin
- Drug-margin- and site-of-care-driven
- Capex intensity
- Moderate
recurring chronic infusion
Characteristics
- Site-of-care shift to lower-cost freestanding infusion.
- Biologics and specialty infusibles drive growth.
- Often an ancillary attached to specialty practices.
M&A deal context
Who’s acquiring
- Infusion & specialty-care platforms
- Specialty MSO acquirers
- PE-backed consolidators
What’s driving deals
- Site-of-care shift to lower-cost infusion.
- Biologics and specialty-drug growth.
- Ancillary-driven specialty-practice consolidation.
Find Oncology Infusion Centers acquisition targets
Search Acquisera’s index for companies classified under Oncology Infusion Centers (4.10.18.4) and build a targeted deal pipeline.
Search companies